| Subject: | FDA Issues a Public Health Advisory about Epoetin alfa (marketed as Procrit, Epogen) and Darbepoetin alfa (marketed as Aranesp) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 28 Nov 2006 - 12:00 am |
| Audience: Oncologists, nephrologists, and other healthcare professionals
Indication: Treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis.
The FDA has notified healthcare professionals of a newly published clinical study in the New England Journal of Medicine about Procrit, an erythropoiesis-stimulating agent (ESA) also known as recombinant human erythropoietin. Procrit, like the other ESAs, Epogen, and Aranesp, increases blood... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
